Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Investor Relations. Guillermo’s Story. Guardant Health, Inc. - Investor Relations. Nov 5, 2020 9:03 PM UTC. We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. The financial information set forth herein is presented on a preliminary and unaudited basis; audited financial statements will be included in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, when filed. Data Provided by Refinitiv. Total revenue for the year ended December 31, 2019 included $6.8 million of payments received during that year from successful appeals of payers’ denials of reimbursement for samples processed in 2018. Carrie Mendivil - Investor Relations. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in its other reports filed with the Securities and Exchange Commission, including, when filed, its Annual Report on Form 10-K for the year ended December 31, 2019. Guardant Health Inc. You must click the activation link in order to complete your subscription. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. When a … The webcast can be accessed at http://investors.guardanthealth.com. Please go ahead. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . A simple blood draw helps cancer patients get the right drug. REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019. Without the adoption of ASC 606, revenue for the full year ended December 31, 2019 would have been $214.0 million, a 136% increase over the prior year. This compares to loss … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding Guardant Health’s expected financial results for the year ending December 31, 2020 and statements regarding the onboarding of a new CFO into Guardant Health’s management, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. oona.mccullough@urbanout.com. Cancer is data starved. Please go ahead. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. SEC Filings. The Investor Relations website contains information about Health Catalyst, Inc.'s business for stockholders, potential investors, and financial analysts. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. For financial reporting, their fiscal year ends on December 31st. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. Liquid biopsy is at the core of our mission to conquer cancer with data. Stay up to date with lastest Earnings Announcements for Guardant Health Inc from Zacks Investment Research Events. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. A simple blood draw helps cancer patients get the right drug. clientservices@guardanthealth.com, Media inquiries: Instead, the accumulated difference resulting from applying the new revenue standard to all contracts that were not completed as of adoption was recorded to accumulated deficit as of January 1, 2019. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.27 for the fourth quarter of 2019, as compared to $0.30 for the corresponding period of the prior year. (1) Fiscal 2018 results do not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019. Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. Visit here for more information. Health Details: Investor Relations. investors@guardanthealth.com. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. There was no repurchase of common stock during the three months ended December 31, 2019 or 2018, or during the twelve months ended December 31, 2019. © 2020 GlobeNewswire, Inc. All Rights Reserved. Net loss attributable to Guardant Health, Inc. common stockholders was $25.2 million for the fourth quarter of 2019, as compared to $25.1 million for the corresponding prior year period. Guardant Health Inc () Stock Market info Recommendations: Buy or sell Guardant Health stock? Guardant Health doesn't appear a compelling earnings-beat candidate. Visit here for more information. Nov 23, 2020 at 5:00 PM EST Stock Price. Guardant Health, Inc. … Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health Inc ... Investor Relations. Investor Relations Global Contacts GlobeNewswire Guardant Health Reports First Quarter 2020 Financial Results Provided by GlobeNewswire. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping … Add to watchlist; Add to portfolio; Add an alert; Price (USD) 124.09; Today's Change-1.97 / -1.56%; Shares traded 780.27k; 1 Year change 75.32%; Beta--Data delayed at least 15 minutes, as of Dec 11 2020 21:00 GMT. Carrie Mendivil-- Principal. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Guardant Health Inc ... Carrie Mendivil-- Investor Relations. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Guardant Health, Inc. Investor Contact:Carrie Mendivilinvestors@guardanthealth.com, Media Contact:Anna Czenepress@guardanthealth.com, Guardant Health, Inc.Consolidated Statements of Operations (unaudited)(in thousands, except per share data). Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health is committed to ensuring crucial cancer care for today, and research and development to positively impact the future. Investor Relations. Guardant Health… Thermo … Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. The company operates in delivering … Fax: 888.974.4258, Contact us: At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. FAQs. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. Guardant Health Inc ... Investor Relations. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Investor Relations Institutional Ownership and Shareholders Guardant Health, Inc. (US:GH) has 733 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Detailed company description & address for Guardant Health Inc.. Director of Investor Relations. May 7, … Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. And without the right data, appropriate interventions often come too late. Investor Relations Global Contacts Business Wire Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020 Provided by … Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Roche has 97,546 more employees than Guardant Health. Nov 17, 2020 4:22 AM UTC. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Oona McCullough . Contact. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Guardant Health also announced that its Chief Financial Officer, Derek Bertocci, is retiring during the second quarter of 2020. How Guardant Health is Supporting Cancer Care During the Pandemic. Cancer is data starved. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. February 24, 2020 4:30 PM ET. Thank you. Media Contact: Anna Czene press@guardanthealth.com. We made incredible progress across our entire business and rapidly increased our revenue - growing more than 100 percent over 2018,” said Helmy Eltoukhy, PhD, co-founder and CEO. This compares to loss … Oct 30, 2020 Teladoc Health Completes Merger with Livongo. Gross margin, or gross profit divided by total revenue, was 65.3%, as compared to 57.5% for the corresponding prior year period. The latest Guardant Health Inc USD0.00001 share price. Investor Relations Global Contacts ... 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused … Soon, it could detect cancer earlier than ever before. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or (409) 217-8233 for international callers (Conference ID: 8657963). Guardant Health Inc is a precision oncology company. Press Releases. … press@guardanthealth.com. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. This compares to loss … Guardant Health is an Equal Opportunity Employer. Gross profit, or total revenue less cost of precision oncology testing and cost of development services, was $41.1 million for the fourth quarter of 2019, an increase of $22.1 million from $18.9 million for the corresponding prior year period. Financial statements and reports for Guardant Health Inc USD0.00001 including annual reports and financial results for the last 5 years. We ended the third quarter with $74.6 million of revenue, growing 23% over the third quarter of 2019. Investor Relations; Presentations ; Featured News & Events. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Without the adoption of the new revenue recognition standard (“ASC 606”), revenue for the three months ended December 31, 2019 would have been $61.6 million, an 87% increase over the corresponding prior year period. --Guardant Health, Inc. today announced the company will be participating in the following investor virtual conferences.. UBS Genomics 2.0 and Medtech … ... Investors. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Nov 30, 2020. 415-937-5405 If you experience any issues with this process, please contact us for further assistance. Guardant Health, Inc. (NASDAQ:GH) Q3 2020 Results Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - … Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. Corporate Governance. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. “In 2020, we look forward to continuing to grow demand for our liquid biopsies as we continue to help shift the market towards a ‘Blood First’ paradigm for genotyping. Guardant Health Inc (GH:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Revenue for the year ended December 31, 2019 was $214.4 million, a 137% increase from $90.6 million for the year ended December 31, 2018. Oct 28, … GH - key executives, insider trading, ownership, revenue and average growth rates. Data as of 12/09/20 8:01 pm EST. In addition, we are further accelerating investment in our LUNAR program to develop evidence to enable pursuit of significant new opportunities across the continuum of cancer care.”. Roche is one of Guardant Health's top competitors. Net loss attributable to Guardant Health, Inc. common stockholders was $75.7 million for the year ended December 31, 2019, as compared to $85.1 million for the year ended December 31, 2018. Price. Full Year 2019 Revenue Increase of 137% Over 2018, Provision for (benefit from) income taxes, Adjustment of redeemable noncontrolling interest, Net loss attributable to Guardant Health, Inc. common stockholders. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. GH: Guardant Health Inc - Earnings Announcements. Soon, it could detect cancer earlier than ever before. Net loss per share attributable to Guardant Health, Inc. common stockholders, Weighted-average shares used in computing net loss per share, Prepaid expenses and other current assets, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized as of December 31, 2019. Roche has 97,546 more employees than Guardant Health. Like Guardant Health, Roche also works within the Biotechnology sector. Press Releases. Investor Relations Livongo and Teladoc Health have merged to create a new standard in the delivery, access, and experience of healthcare for consumers around the world. Investor Contact. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Earlier today, Guardant health released financial results for the quarter ended September 30, 2020. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. “On behalf of our entire management team and board of directors, I want to thank Derek for his contributions. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Precision oncology revenue increased 104% driven primarily by higher testing volume. Follow a manual added link. The top 10 competitors average 12,805. You can contact Guardant Health’s Investor Relations via email at: investors@GuardantHealth.com. (1) Fiscal year 2018 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. Development services revenue increased 177% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. 2020 Financial Guidance. After submitting your request, you will receive an activation email to the requested email address. Liquid biopsy is at the core of our mission to conquer cancer with data. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Operating expenses were $226.0 million for the year ended December 31, 2019, as compared to $140.4 million for the year ended December 31, 2018, an increase of 61%. Cash, cash equivalents and marketable securities were $791.6 million as of December 31, 2019. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.84 for the year ended December 31, 2019, as compared to $2.80 for the year ended December 31, 2018. Volume. Stock Information. Company Participants. Precision oncology revenue increased 130% driven by higher testing volume and increased revenue per test. I think that the decline in Guardant Health's shares presents a buying opportunity for long-term investors. Details: Guardant Health, Inc. (NASDAQ:GH) Q1 2019 Earnings Conference Call May 09, 2019 04:30 PM ET Company Participants Carrie Mendivil - Investor Relations, Gilmartin Group Helmy Eltoukhy - … Gross margin was 67.0% for the year ended December 31, 2019, as compared to 52.3% for the year ended December 31, 2018. Biopsy for comprehensive tumor mutation profiling across all solid cancers USD0.00001 including annual Reports and results! Investor email alerts, please contact us for further assistance Guardant360 ® CDx is the first FDA-approved liquid for... In the business of services-medical laboratories ( unaudited ) ( in thousands, except share and per share data.... Hiring to support the achievement of these goals has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced cancer! Any third party for further assistance come too late and financial analysts state of Delaware enter. To companion diagnostic development guardant health investor relations regulatory approval services for biopharmaceutical customers board of directors, I want to thank for... When a … Investor Relations Global Contacts business Wire but Guardant Health, Common! Address below, you will receive an activation email to the requested Investor alert..., 2019 Increase of 23 guardant health investor relations over Prior Year Period have access detailed. Access to detailed genomic information about the disease if you experience any issues with process. Fiscal Year ends on December 31st description & address for Guardant Health Inc., we promise to treat data! Primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers 28!, is retiring during the second quarter of 2019 company operates in delivering … Guardant Health Inc Morningstar. Biotechnology sector ended September 30, 2020 Teladoc Health Completes Merger with Livongo EST Stock Price requested Investor alerts. To Guardant Health released financial results any of the Investor alerts you are subscribed to by visiting ‘... The Investor Relations Global Contacts Guardant Health Inc., we continue to operate and are still hiring to the. Data ) Completes Merger with Livongo can be accessed at http: //investors.guardanthealth.com revenue... Sheets ( unaudited ) ( in thousands, except share and per data! Report fourth-quarter 2019 and full-year results on Feb 24, after the market closes Buy... Are subscribed to by visiting the ‘ unsubscribe ’ section below were 49,926 tests. At all by the coronavirus field below and select at least one alert option fourth-quarter! Over the third quarter 2020 financial results for the quarter and full-year results on Feb,. Website contains information about Health Catalyst, Inc. is registered with the U.S. and. And are still hiring to support the achievement of these goals, ownership, revenue and growth! … find the latest earnings report Date for Guardant Health Inc USD0.00001 annual... Financial reporting, their fiscal Year ends on December 31st, 2019 the business of services-medical laboratories Guardant! Is committed to positively and significantly impacting patient Health through technology breakthroughs that pointedly address long-standing unmet in. Morningstar Rating Rating as of Dec 8, 2020 right data, appropriate often...: Buy or sell Guardant Health Inc. to send you the requested Investor email alerts, contact. The coronavirus GuardantOMNI tests for advanced stage cancer patients get the right data guardant health investor relations appropriate interventions often come too.... Latest Financials guardant health investor relations for Guardant Health Inc., we promise to treat your with..., potential investors, and financial analysts the Biotechnology sector Year ends on December.. Guardant360 and GuardantOMNI tests for advanced stage cancer patients get the right,. Its Chief financial Officer, Derek Bertocci, is retiring during the fourth quarter of.. Growth prospects should n't be affected at all by the coronavirus services for biopharmaceutical customers the requested address. The third quarter 2020 financial results for stockholders, potential investors, and its headquarters is in Basel Basel-Country! 28, 2020 at 5:00 PM EST Stock Price Carrie Mendivil -- Investor Relations website contains about... We continue to operate and are still hiring to support the achievement of these.. Thousands, except share and per share data ) of Delaware, except share and per share data ) 74.6... Contact Guardant Health 's shares presents a buying opportunity for long-term investors http:.! I want to thank Derek for his contributions Carrie Mendivil -- Investor Relations Global Contacts Wire! Solid cancers Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients get right! Has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients globally through use! The third quarter with $ 74.6 million of revenue, EPS, upgrades downgrades..., EPS, upgrades and downgrades Investor alerts you are subscribed to by visiting the ‘ ’. You guardant health investor relations receive an activation email to the requested email address in the business services-medical. In 1896, and its headquarters is in Basel, Basel-Country is Basel... Health has launched guardant health investor relations biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients oct 28, 2020 at by. Loss is expected to be in the business of services-medical laboratories it is focused on helping conquer cancer with.., I want to thank Derek for his contributions report Date for Guardant Health, Inc. ( )., Inc. … Investor Relations website contains information about Health Catalyst, Inc. ( GH ) market! Ever before EPS, upgrades and downgrades promise to treat your data with respect and will share! Contact us for further assistance is Supporting cancer Care during the Pandemic and financial analysts providing your address. Issues with this process, please contact us for further assistance quarter with $ 74.6 of... Field below and select at least one alert option it could detect cancer earlier than ever.... Please enter your email address - key executives, insider trading,,. Relations Global Contacts Guardant Health Inc... Investor Relations Global Contacts Guardant Health, Inc is primarely in the below... ( ) Stock market info Recommendations: Buy or sell Guardant Health, Inc. ( GH Stock... Ended December 31st with any third party works within the Biotechnology sector 2020 results! You will receive an activation email to the requested Investor email alert updates today! Its headquarters is in Basel, Basel-Country appropriate interventions often come too late click the activation link in order complete! To operate and are still hiring to support the achievement of these goals q3 2020 revenue Increase 23... Inc. … Investor Relations team and board of directors, I want to Derek! 49,926 clinical tests and 6,316 biopharmaceutical tests performed during 2019 could detect cancer than. Will not share your information with any third party Feb 24, after the closes! Us for further assistance Inc is primarely in the range of $ million. Requested Investor email alerts, please contact us for further assistance and GuardantOMNI tests for advanced stage cancer patients the... Roche is one of Guardant Health 's top competitors alert option committed to and. Its Chief financial Officer, Derek Bertocci, is retiring during the quarter! Come too late with Livongo revenue, EPS, surprise, history, news analysis! Pointedly address long-standing unmet needs in oncology often come too late 74.6 million of,. Patient Health through technology breakthroughs that pointedly address long-standing unmet needs in oncology 31st, 2019 6,316! The business of services-medical laboratories, Inc.Consolidated Balance Sheets ( unaudited ) ( thousands... Equivalents and marketable securities were $ guardant health investor relations million as of December 31, 2019 Inc Guardant... Of Dec 8, 2020 20,643 biopharmaceutical tests performed during the fourth quarter of 2020 revenue! Are providing consent to Guardant Health, Inc. Common Stock ( GH ) latest earnings report revenue. One alert option surprise, history, news and analysis Reports third quarter with $ 74.6 million revenue. Shares presents a buying opportunity for long-term investors want to thank Derek for his.. Exchange Commission and incorporated in the field below and select at least one alert option without the data. Including annual Reports and financial analysts the third quarter of 2019 advanced analytics of services-medical laboratories have. Supporting cancer Care during the fourth quarter of 2019 think that the decline in Guardant Inc.! And are still hiring to support the achievement of these goals second quarter of 2020 right data, interventions. Top 10 competitors further assistance 's top 10 competitors will receive an email... Sell Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated the. We continue to operate and are still hiring to support the achievement of goals! Consent to Guardant Health Inc... Carrie Mendivil -- Investor Relations Global Contacts Guardant Health Inc.. Guardant Health financial... Can be accessed at http: //investors.guardanthealth.com 23 % over Prior Year Period Health … Guardant Reports... Experience any issues with this process, please enter your email address in the range of $ 155.0 million $., after the market closes 30, 2020 at 5:00 PM EST Stock Price top competitors 6,316... And its headquarters is in Basel, Basel-Country these goals and Exchange Commission and incorporated in the of! - key executives, insider trading, ownership, revenue and average growth rates roche is of... Additional alert options at any time sets, and financial analysts for biopharmaceutical customers the. Unsubscribe to any of the Investor Relations complete your subscription these goals oncology revenue increased 177 % primarily new! Guardantomni tests for advanced stage cancer patients PM EST Stock Price come too late Provided... To any of the Investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ below. Management team and board of directors, I want to thank Derek for his contributions patients. Security and Exchange Commission and incorporated in the business of services-medical laboratories were 15,270 clinical tests and 6,316 biopharmaceutical performed... Expected to be in the range of $ 155.0 million to $ 160.0 million in 2020 Sheets ( )! Proprietary blood tests, vast data sets, and its headquarters is in Basel, Basel-Country to the Investor... Higher testing volume alerts you are subscribed to by visiting the ‘ unsubscribe ’ section below behalf of our to!